FIELD: biotechnology.
SUBSTANCE: invention relates to a method of increasing the macrophage M1 pool in a patient suffering from conditions associated with undesired M2 activation. The presented method includes a stage of administrating an effective quantity of antibodies to the patient. The effective quantity of antibodies should be capable of binding with CSF-1R, where the specified antibody is an antibody that binds with at least one epitope, located among the positions of amino acids from 20 to 39 ID NO: 23.
EFFECT: invention can be used to stimulate an M1-type immune response.
11 cl, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINS CSF-1R | 2012 |
|
RU2621859C2 |
| CSF-1R ANTIBODY | 2009 |
|
RU2547586C2 |
| BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
| ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | 2012 |
|
RU2658603C2 |
| ANTIBODIES PRIMARILY BINDING TO EXTRACELLULAR DOMAIN 4 OF HUMAN CSF-1R, AND USING THEM | 2010 |
|
RU2565541C2 |
| HUMAN ONCOSTATIN M ANTIBODIES AND METHODS OF USE THEREOF | 2011 |
|
RU2600444C2 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617971C2 |
| MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CSF-1R | 2020 |
|
RU2751249C1 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617966C2 |
